Ophthalmology Drugs Companies

The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market is driven by several key factors, including an increasing population affected by eye conditions, a strong pipeline of drugs being developed for ophthalmology indications, and rising investments along with strategic collaborations for innovation and advancements in therapy development against ophthalmological indications.

Some of the major players in the ophthalmology drugs industry with a strong international presence are Regeneron Pharmaceuticals Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany). Companies in the ophthalmology drugs sector are leveraging both organic and inorganic growth strategies to enhance their global footprint and fortify their market positions. This approach includes forming strategic partnerships, executing acquisitions, entering into agreements & collaborations, and seeking approvals for as well as launching new products. As a result of these initiatives, organizations focus on enhancing their ophthalmology drug portfolios and improving market access while establishing a significant presence in developed and emerging markets.

To know about the assumptions considered for the study download the pdf brochure

In 2023, Regeneron Pharmaceuticals, Inc. launched Eylea HD (aflibercept 8 mg) in the US, designed to provide longer-lasting effects with fewer injections. Early trial data from the PHOTON and PULSAR studies showed promising results, allowing for dosing intervals of up to 16 weeks. This would aid in building the competitive resilience of Eylea HD against newer products like Roche’s Vabysmo.

Roche, a prominent player in the ophthalmology drugs sector, has significantly strengthened its position in the ophthalmology drugs market with the FDA approval and rapid rollout of Vabysmo (faricimab) in 2022. In addition to Vabysmo, Roche markets Luxturna, the only approved gene therapy for an ophthalmic indication, specifically for biallelic RPE65 mutation-associated retinal dystrophy with viable retinal cells.

Bayer AG plays a key role in the ophthalmology drugs market by marketing Eylea and investing in advanced therapies such as cell and gene therapy. The company has partnered with BlueRock Therapeutics (its wholly owned subsidiary) to drive innovation in the field. In February 2025, Bayer and BlueRock announced that their investigational therapy, OpCT-001, received Fast Track designation from the US FDA. This therapy is derived from induced pluripotent stem cells (iPSCs) and is designed to treat primary photoreceptor diseases. Such developments highlight Bayer’s strategic focus on next-generation treatments and reinforce its commitment to securing long-term leadership in the ophthalmology drugs market.

Market Ranking

The ophthalmology drugs market is characterized by intense competition, with four key players commanding a substantial share of global revenues, estimated to be between 80% and 85% of the total market. These leading companies reinforce their market positions through strategic investments, regulatory advancements, and extensive partnerships. Notably, Regeneron Pharmaceuticals, Inc. maintains a robust presence, bolstered by its products in the ophthalmology drugs market. Additionally, the 2023 launch of Eylea HD is expected to aid Regeneron in maintaining its strategic position in the market. In leveraging its Genentech arm, Roche is at the forefront of biologics innovation with Vabysmo, a dual-action therapy offering improved durability and fewer injections for wet AMD and DME. Bayer is pushing boundaries through its involvement in both anti-VEGF therapies and cutting-edge cell therapy, venturing into other non-conventional modalities. Meanwhile, Novartis remains a key global force, with an extensive ophthalmology portfolio that includes Beovu and Luxturna and a growing emphasis on gene therapy and sustained delivery platforms.

The remainder of the market, comprising approximately 15–20%, is populated by various regional players and emerging biopharmaceutical companies leveraging partnerships and targeting niche indications to secure a foothold. The competitive dynamics are evolving, driven by the patent expirations of significant biologics, shifting regulatory frameworks, and a growing demand for cost-effective biologic alternatives across indications such as age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, among others. Companies must focus on innovation, integration, and responsiveness to market demands to thrive in this transforming environment.

Related Reports:

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com